Massimo Breccia

Pubblicazioni

Titolo Pubblicato in Anno
Efficacy and Safety of Luspatercept in Adult Patients with Transfusion-Dependent Anemia Due to Very Low, Low and Intermediate Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts, Who Had an Unsatisfactory Response to or Are Ineligible for Erythropoietin-Based Therapy: A Retrospective Multicenter Study By Fondazione Italiana Sindromi Mielodisplastiche (FiSiM ETS) BLOOD 2022
Editorial: Risk-stratification in myelodysplastic syndromes FRONTIERS IN ONCOLOGY 2022
Treatment-free remission in chronic myeloid leukemia patients treated front-line with nilotinib: 10-year follow- up of the GIMEMA CML 0307 study HAEMATOLOGICA 2022
Myelodysplastic Syndromes with Isolated 20q Deletion: A New Clinical-Biological Entity? JOURNAL OF CLINICAL MEDICINE 2022
CML-164 Dihydroorotate Dehydrogenase Inhibition Reveals Metabolic Vulnerability in Chronic Myeloid Leukemia CLINICAL LYMPHOMA MYELOMA & LEUKEMIA 2022
CML-466 Asciminib Provides Durable Molecular Responses in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With the T315I Mutation: Updated Efficacy and Safety Data From a Phase I Trial CLINICAL LYMPHOMA MYELOMA & LEUKEMIA 2022
Covid-19 in Philadelphia-negative myeloproliferative neoplasms: a GIMEMA survey on incidence, clinical management and vaccine LEUKEMIA 2022
Clinical utility and physician perceptions of a digital platform for electronic patient-reported outcomes monitoring in patients with hematologic malignancies in real-world practice. BLOOD 2021
Acute promyelocytic leukemia (APL) in very old patients: real-life behind protocols ACTA ONCOLOGICA 2021
New dead/H-Box helicase gene (Ddx41) mutation in an italian family with recurrent leukemia. LEUKEMIA & LYMPHOMA 2021
Long-term follow-up of late chronic phase chronic myeloid leukemia patients treated with imatinib after interferon failure: a single center experience LEUKEMIA & LYMPHOMA 2021
Therapeutic strategies in low and high-risk MDS: What does the future have to offer? BLOOD REVIEWS 2021
Early intracranial haemorrhages in acute promyelocytic leukaemia: analysis of neuroradiological and clinico-biological parameters BRITISH JOURNAL OF HAEMATOLOGY 2021
Real-life evaluation of potential candidates for treatment discontinuation in chronic myeloid leukemia: the impact of age and long-term follow-up LEUKEMIA & LYMPHOMA 2021
Management of myelofibrosis and concomitant advanced cutaneous squamous cell carcinoma with ruxolitinib associated with cemiplimab ANNALS OF HEMATOLOGY 2021
Validation and reference values of the EORTC QLQ-CML24 questionnaire to assess health-related quality of life in patients with chronic myeloid leukemia LEUKEMIA & LYMPHOMA 2021
Smoothened inhibitor erismodegib combined with nilotinib in patients with chronic myeloid leukemia resistant/intolerant to at least one prior tyrosine kinase inhibitor: a phase 1b study LEUKEMIA & LYMPHOMA 2021
Real-World Analysis of the Clinical and Economic Burden of Later Line in Chronic Myeloid Leukemia Patients in Italy BLOOD 2021
First Interim Analysis of the Italian Dante Study: De-Escalation before Treatment-Free Remission in Patients with Chronic Myeloid Leukemia Treated with First-Line Nilotinib BLOOD 2021
Multicenter, Prospective and Retrospective Observational Cohort Study of Ponatinib in Patients with CML in Italy: Primary Analysis of the Oiti Trial BLOOD 2021

© Università degli Studi di Roma "La Sapienza" - Piazzale Aldo Moro 5, 00185 Roma